Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes

Authors

  • João Agostinho Machado-Neto University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Fabiola Traina University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Mariana Lazarini University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Paula de Melo Campos University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Katia Borgia Barbosa Pagnano University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Irene Lorand-Metze University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Fernando Ferreira Costa University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center
  • Sara T Olalla Saad University of Campinas; National Institute of Blood; Hematology and Hemotherapy Center

DOI:

https://doi.org/10.1590/S1807-59322011000500014

Keywords:

Hematopoietic Disorder, Acute Leukemia, Myelodysplasia, Mutations, Bone Marrow

Abstract

INTRODUCTION: Myelodysplastic syndromes encompass a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, refractory cytopenia and a tendency to progress toward acute myeloid leukemia. The accumulation of genetic alterations is closely associated with the progression of myelodysplastic syndromes toward acute myeloid leukemia. OBJECTIVE: To investigate the presence of mutations in the points most frequent for mutations (hotspot mutations) in phosphatidylinositol-3-kinase (PI3K), Janus kinase 2 (JAK2), FMS-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1), which are involved in leukemia and other cancers, in a population of Brazilian MDS patients. METHODS: Fifty-one myelodysplastic syndromes patients were included in the study. According to French-American-British classification, the patients were distributed as follows: 31 with refractory anemia, 8 with refractory anemia with ringed sideroblasts, 7 with refractory anemia with excess blasts, 3 with refractory anemia with excess blasts in transformation and 2 with chronic myelomonocytic leukemia. Bone marrow samples were obtained and screened for the presence of hotspot mutations using analysis based on amplification with the polymerase chain reaction, sequencing, fragment size polymorphisms or restriction enzyme digestion. All patients were screened for mutations at the time of diagnosis, and 5 patients were also screened at the time of disease progression. RESULTS: In the genes studied, no mutations were detected in the patients at the time of diagnosis. One patient with chronic myelomonocytic leukemia was heterozygous for a Janus kinase 2 mutation after disease progression. CONCLUSIONS: These results show that hotspot mutations in the PI3K, JAK2, FLT3 and NPM1 genes are not common in MDS patients; nevertheless, JAK2 mutations may be present in myelodysplasia during disease progression.

Downloads

Download data is not yet available.

Downloads

Published

2011-01-01

Issue

Section

Clinical Sciences

How to Cite

Machado-Neto, J. A., Traina, F., Lazarini, M., Campos, P. de M., Pagnano, K. B. B., Lorand-Metze, I., Costa, F. F., & Saad, S. T. O. (2011). Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes . Clinics, 66(5), 793-799. https://doi.org/10.1590/S1807-59322011000500014